Skip to content

Yi Liu

Yi Liu

Company: Wellspring Biosciences

Job title: Chief Scientific Officer


Yi Liu, Ph.D., is Chief Scientific Officer of Wellspring Biosciences Inc., a private biopharmaceutical company he co-founded in July 2012.  From October 2014 to November 2018, Dr. Liu served as Chief Scientific of Kura Oncology, a public company he co-founded in August 2014.   Dr. Liu also co-founded Intellikine, Inc., a private biopharmaceutical company, where he served as Vice President of Drug Discovery from 2007 to May 2012, until its acquisition by Takeda Pharmaceuticals.  Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation. Earlier in his career, he held senior scientist positions at both SGX Pharmaceuticals, Inc., a public biopharmaceutical company which was acquired by Eli Lilly and Company in 2008, and Curagen Corporation, a public biopharmaceutical development company. Dr. Liu received his Ph.D. in Biochemistry from Princeton University, his MSc in computational chemistry from Beijing University and his BE in Chemical Engineering from Tsinghua University.




Drugging Undruggable with a Covalent Approach 10:00 am

Developed a covalent approach to selectively target KRAS G12C mutant protein First to demonstrate KRAS G12C mutant proteins cycle between active GTP state and inactive GDP state Explored KRAS dependency in mouse tumor models  Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.